Evidence map›Paper›PMID 26502714›Full record

Trial reportBMC infectious diseases2015

Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.

Akintunde Sowunmi, Kazeem Akano, Adejumoke I Ayede, Godwin Ntadom, Bayo Fatunmbi, Temitope Aderoyeje, Elsie O Adewoye

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Evidencing the Role of Erythrocytic Apoptosis in Malarial Anemia.Frontiers in cellular and infection microbiology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Akintunde SowunmiDepartment of Pharmacology & Therapeutics, University of Ibadan, Ibadan, Nigeria. akinsowunmi@hotmail.com.
Kazeem AkanoDepartment of Pharmacology & Therapeutics, University of Ibadan, Ibadan, Nigeria. heycarnow@yahoo.com.
Adejumoke I AyedeDepartment of Paediatrics, University of Ibadan, Ibadan, Nigeria. idayede@yahoo.co.uk.
Godwin NtadomFederal Ministry of Health, Abuja, Nigeria. ntadomg@yahoo.com.
Bayo FatunmbiWorld Health Organization, Regional Office for the Western Pacific, Khan Daun Penh, Phnom Penh, Cambodia. fatunmbib@wpro.who.int.
Temitope AderoyejeDepartment of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria. tope_forever@yahoo.com.
Elsie O AdewoyeDepartment of Physiology, University of Ibadan, Ibadan, Nigeria. elolade@yahoo.com.
University of Ibadan · NGFederal Ministry of Health · NGUniversity College Hospital, Ibadan · NGWorld Health Organization Regional Office for the Western Pacific · PH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundArtemisinin-based combination treatments (ACTs) or intravenous artesunate are used in over 100 countries for uncomplicated or severe falciparum malaria. Although intravenous artesunate may cause delayed haemolytic anaemia, there is little evaluation of the temporal changes in haematocrit following ACTs.

methodsClinical and parasitological parameters were measured before and following treatment of uncomplicated falciparum malaria in children with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL) over 6-weeks. Changes in haematocrit were characterized in individual patients based on a haematocrit <30 % or ≥30 % before and following treatment. Kinetics of the deficit in haematocrit from <30 % until attainment of ≥30 % were estimated by a non-compartment model.

resultsIn 248 of 1180 children eligible for evaluation, common temporal patterns were: no change or increase in haematocrit from ≥ 30 % [50 % of patients], haematocrit >30 % at presentation declining to <30 % within 2 weeks (early monophasic fall) [19 % of patients], and haematocrit <30 % at presentation increasing to ≥ 30 % [23 % of patients]. Haematocrit >30 % at presentation declining to <30 %, 3-5 weeks later (late monophasic fall) occurred in 7 children (3 %). Fall in haematocrit ≥5 units following treatment occurred in 57 children [23 %] between 14 and 28 days after treatment began. Baseline parasitaemia and proportion with > 100,000μL(-1) asexual forms were significantly higher in children with ≥5 units compared to <5 units fall in haematocrit 21 or 28 days after treatment began. Irrespective of pattern, declines in haematocrit deficit from <30 % were mono-exponential, with similar half-times for AA- and AL-treated children (1.32 d versus 1.14 d). Anaemia half-time correlated significantly positively with anaemia recovery time in the same patients (r = 0.55, P < 0.0001). Bland-Altman analysis of 9 or 10 multiples of anaemia half-time and anaemia recovery times showed narrow limit of agreement with insignificant biases (P = 0.19 or 0.63, respectively).

conclusionsIn uncomplicated falciparum malaria, increases or falls in haematocrit are common following ACTs. Falls in haematocrit ≥ 5 units are common and may or may not result in early or late anaemia. In children who recovered from acute falciparum malaria-associated anaemia following ACTs, decline in haematocrit deficit is mono-exponential. TRIALS REGISTRATION: Pan African Clinical Trial Registry PACTR201508001188143 , 3 July 2015; PACTR201508001191898 , 7 July 2015 http://www.pactr.org .

Indexed as

HematocritAdministration, IntravenousAdolescentAmodiaquineAnemiaAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsChildChild, PreschoolCombined Modality TherapyDrug CombinationsDrug Therapy, CombinationEthanolaminesFemaleFluorenesAmodiaquineamodiaquine, artesunate drug combinationAntimalarialsArtemether, Lumefantrine Drug CombinationartemisininArtemisininsDrug CombinationsEthanolaminesFluorenes

Identifiers

PMID26502714
PMCPMC4620624
OpenAlexW1859841916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.